(Q48373616)

11 February 2018

title

Non-motor features of Parkinson's disease: depression and dementia (English)

1 reference

11 February 2018

0 references

1 reference

1

Heinz Reichmann

1 reference

11 February 2018

Christine Schneider

2

1 reference

11 February 2018

Matthias Löhle

series ordinal

3

1 reference

11 February 2018

publication date

1 December 2009

1 reference

11 February 2018

Parkinsonism and Related Disorders

published in

1 reference

11 February 2018

volume

15 Suppl 3

1 reference

11 February 2018

page(s)

S87-92

1 reference

11 February 2018

Epidemiology of Parkinson's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Comorbidity of the nonmotor symptoms of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

The association between motor subtypes and psychopathology in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Depression and Parkinson's disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

A systematic review of prevalence studies of depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

The occurrence of depression in Parkinson's disease. A community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

An estimate of the incidence of depression in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Non-recognition of depression and other non-motor symptoms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Depression rating scales in Parkinson's disease: critique and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Depression associated with Parkinson's disease: clinical features and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Managing the neuropsychiatric symptoms of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

The mesolimbic dopamine system as a target for rapid antidepressant action.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

A controlled trial of antidepressants in patients with Parkinson disease and depression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

SSRIs in the treatment of depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Effect of reboxetine on depression in Parkinson's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Bupropion in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Moclobemide and selegeline in the treatment of depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Treatment of depression in Parkinson's disease with moclobemide: A pilot open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Psychotic symptoms in Parkinson's disease. From description to etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Prospective study of hallucinations and delusions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Hallucinosis in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Olanzapine treatment for dopaminergic-induced hallucinations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

A systematic review of prevalence studies of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Risk of dementia in Parkinson's disease: a community-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Antecedent clinical features associated with dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

The Frequency and Associated Risk Factors for Dementia in Patients With Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Motor impairment in PD: relationship to incident dementia and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Neuropsychological characteristics of preclinical dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Neuropsychological prediction of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Memory and executive function impairment predict dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Parkinson's disease dementia: a diminished role for the Lewy body

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Clinical diagnostic criteria for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Cholinergic dysfunction in diseases with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Cholinesterase inhibition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

Lewy body dementia and Parkinson's disease with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970789-8

7 January 2021

10.1016/S1353-8020(09)70789-8

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018